Portraying Persons Who Inject Drugs Recently Infected with Hepatitis C Accessing Antiviral Treatment: A Cluster Analysis

Table 1

Characteristics of participants and comparative analyses according to treatment initiation ().

	Frequency distribution						Comparison tests
	Total sample ()		Treatment not initiated (65%)		Treatment initiated (35%)		value
		%		%		%
Age categories
<30 years old	28	46.7	21	53.8	7	33.3
30–39 years old	15	25.0	9	23.1	6	28.6	0.311
>40 years old	17	28.3	9	23.1	8	38.1	0.133
Gender
Female	15	25.0	11	28.2	4	19.0	0.437
Male	45	75.0	28	71.8	17	81.0
Education
Secondary or less	44	73.3	30	76.9	14	66.7	0.397
College or above	16	26.7	9	23.1	7	33.3
Housing
Stable housing (home, apartment, room)	25	41.7	18	46.2	7	33.3
Temporary housing (therapy, prison, shelter)	22	36.7	12	30.8	10	47.6	0.217
Homeless	13	21.7	9	23.1	4	19.0	0.858
Alcohol consumption	36	60.0	23	59.0	13	61.9	0.825
IV drugs consumed
IV heroine	29	48.3	19	48.7	10	47.6	0.935
IV cocaine	53	88.3	34	87.2	19	90.5	0.705
Vaccines received
Hepatitis B vaccine	17	28.3	7	17.9	10	47.6	0.015
Quality of life scores
PCS mean (SD)	46,4	10.2	45.6	9.8	47.9	10.9	0.389
MCS mean (SD)	33,9	13.9	34.0	14.2	33.9	13.8	0.985
Methadone	20	33.3	10	25.6	10	47.6	0.085
Having been followed up in the 6 prior months by a family physician	11	18.3	6	15.4	5	23.8	0.424

Pearson chi-square.